Latest Medtech News
Johnson & Johnson has launched the Shockwave C2 Aero Fly Coronary IVL Catheter in the U.S., a next-generation intravascular lithotripsy (IVL) catheter for treating calcified coronary artery lesions. The company says the device delivers pulses at 2 Hz, double the speed of prior coronary IVL catheters, and cuts pause time between pulsing cycles to five seconds, a 50% reduction. J&J reports that treatment time falls from 230 seconds to 115 seconds, while maintaining the safety and effectiveness of earlier catheters.
As an executive search partner to the MedTech industry, Guided Solutions keeps a close eye on stories like this one. Subscribe to our Industry Insights for weekly coverage.
The change targets a specific clinical issue. During IVL, balloon inflation temporarily blocks blood flow, and shorter inflation time reduces the period in which patients may experience ischemic symptoms such as chest pain. The new catheter builds on the Shockwave C2 Aero platform’s deliverability, crossability, and repositioning features.
For J&J, the launch refines a technology the company acquired with Shockwave Medical in 2024 for $13.1 billion. Mike Lang, Worldwide President of Circulatory Restoration, described the aim as an “increasingly efficient, predictable platform” for complex coronary care. Cardiovascular has led J&J MedTech’s growth in the first half of 2026.
For the broader MedTech space, the launch reflects pressure on cath labs to handle more complex cases at higher volumes. The company will feature the catheter at TCT 2026 in San Diego, October 31 to November 3.
